1-5 of 5
Andrew I. Damokosh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study

Clinical Trials & Observations
Austin G. Kulasekararaj, Anita Hill, Scott T. Rottinghaus, Saskia Langemeijer, Richard Wells, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong Wook Lee, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeff Szer, Antonio Risitano, Shinji Nakao, Eric Bachman, Lori Shafner, Andrew I. Damokosh, Stephan Ortiz, Alexander Röth, Regis Peffault de Latour
Journal: Blood
Blood (2019) 133 (6): 540–549.
https://doi.org/10.1182/blood-2018-09-876805
Published: 2019
Includes: Supplemental data
Journal Articles

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Robert A. Brodsky, MD, Regis Peffault De Latour, Scott T. Rottinghaus, MD, Alexander Röth, MD, Antonio M. Risitano, MD PhD, Ilene C. Weitz, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jaroslaw P. Maciejewski, Jeffrey Szer, MBBS, Jong-Wook Lee, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Lori Volles, MD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Lori Shafner, PhD, Anita Hill, MD PhS, Hubert Schrezenmeier, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2330.
https://doi.org/10.1182/blood-2018-99-110874
Published: 2018
Journal Articles

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Anita Hill, MD PhS, Scott T. Rottinghaus, MD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong-Wook Lee, MD PhD, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeffrey Szer, MBBS, Antonio M. Risitano, MD PhD, Shinji Nakao, MD PhD, Eric Bachman, Lori Shafner, PhD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Alexander Röth, MD, Regis Peffault De Latour
Journal: Blood
Blood (2018) 132 (Supplement 1): 625.
https://doi.org/10.1182/blood-2018-99-119147
Published: 2018
Journal Articles

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Ilene C. Weitz, MD, Aleksandr Kulagin, Shinji Nakao, MD PhD, Caroline I. Piatek, MD, Jeffrey Szer, MBBS, Scott T. Rottinghaus, MD, Lori Volles, MD, Andrew I. Damokosh, PhD, Rasha Aguzzi, MS, Loree Larratt, MD, Antonio M. Risitano, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 627.
https://doi.org/10.1182/blood-2018-99-110623
Published: 2018
Journal Articles

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Alexander Roeth, MD, Scott T. Rottinghaus, MD, Anita Hill, MBChB (Hons), PhD, Jin Seok Kim, MD PhD, Hubert Schrezenmeier, MD, Louis Terriou, MD, Alvaro Urbano-Ispizua, MD, Richard A. Wells, MD DPhil, Jun Ho Jang, MD PhD, Jeff Szer, MB, BS, FRACP, Rasha Aguzzi, MS, Eric Scott Bachman, MD PhD, Andrew I. Damokosh, PhD, Lori Shafner, PhD, Jong-Wook Lee, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3482.
https://doi.org/10.1182/blood.V130.Suppl_1.3482.3482
Published: 2017